Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 10/20 | 1.00 |
| ▸ | BACE1 | P56817 | 5/20 | 1.00 |
| ▸ | MMP2 | P08253 | 5/20 | 1.00 |
| ▸ | MMP7 | P09237 | 5/20 | 1.00 |
| ▸ | MMP14 | P50281 | 5/20 | 1.00 |
| ▸ | BCL2 | P10415 | 4/20 | 1.00 |
| ▸ | PSMB5 | P28074 | 4/20 | 1.00 |
| ▸ | SNCA | P37840 | 4/20 | 1.00 |
| ▸ | PGD | P52209 | 4/20 | 1.00 |
| ▸ | MET | P08581 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | RECQL | P46063 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 1.00 |
| ▸ | PKM | P14618 | 3/20 | 1.00 |
| ▸ | PKMYT1 | Q99640 | 2/20 | 1.00 |
| ▸ | PGAM1 | P18669 | 2/20 | 1.00 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Epigalocatechin Gallate SCHEMBL29389587 | 1.00 | DYRK1A (1.00) | DYRK1ABACE1MMP2MMP7MMP14 | |
| Gallocatechin Gallate SCHEMBL30977114 | 1.00 | DYRK1A (1.00) | DYRK1ABACE1MMP2MMP7MMP14 | |
| Epigalocatechin Gallate SCHEMBL30014282 | 1.00 | DYRK1A (1.00) | DYRK1ABACE1MMP2MMP7MMP14 | |
| Epigalocatechin Gallate SCHEMBL30909383 | 1.00 | DYRK1A (1.00) | DYRK1ABACE1MMP2MMP7MMP14 | |
| Epigalocatechin Gallate SCHEMBL14423426 | 1.00 | DYRK1A (1.00) | DYRK1ABACE1MMP2MMP7MMP14 | |
| Epigalocatechin Gallate SCHEMBL35258 | 1.00 | DYRK1A (1.00) | DYRK1ABACE1MMP2MMP7MMP14 | |
| Gallocatechin Gallate SCHEMBL49461 | 1.00 | DYRK1A (1.00) | DYRK1ABACE1MMP2MMP7MMP14 | |
| Epigalocatechin Gallate SCHEMBL13624466 | 1.00 | DYRK1A (1.00) | DYRK1ABACE1MMP2MMP7MMP14 | |
| Epigalocatechin Gallate SCHEMBL8426376 | 1.00 | DYRK1A (1.00) | DYRK1ABACE1MMP2MMP7MMP14 | |
| Epigalocatechin Gallate SCHEMBL29410018 | 1.00 | DYRK1A (1.00) | DYRK1ABACE1MMP2MMP7MMP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012095388-A2 | COMPOUNDS FOR TREATMENT OF FELINE LEUKEMIA IN FELIDAE | Universität Zürich (CH) | 2012-07-19 | — | — | WO | claimed |
| CN-119039264-A | Method for separating and purifying flavonoid components of polygonum hydropiper | 西藏自治区农牧科学院农产品开发与食品科学研究所 | 2024-11-29 | — | — | CN | disclosed |
| WO-2023002500-A1 | SINGLE PROCESS FOR SEQUENTIAL EXTRACTION OF PRODUCTS FROM GREEN TEA LEAVES | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2023-01-26 | — | — | WO | disclosed |
| WO-2023288020-A1 | COMPOSITIONS AND METHODS FOR ANTIOXIDANT AND ANTI-INFLAMMATORY THERAPEUTICS | AVANTI BIOSCIENCES INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| US-20180000774-A1 | METHODS OF TREATING COGNITIVE AND BEHAVIORAL IMPAIRMENT IN DOWN SYNDROME AND ALZHEIMERS DISEASE PATIENTS | AVANTI BIOSCIENCES, INC (US) | 2018-01-04 | — | — | US | disclosed |
| US-20160228456-A1 | COMBINATION | NOVARTIS PHARMA AG (CH) | 2016-08-11 | — | — | US | disclosed |
| US-20160228456-A1 | COMBINATION | NOVARTIS PHARMA AG (CH) | 2016-08-11 | — | — | US | disclosed |
| US-9399021-B2 | Pharmaceutical composition | NOVARTIS AG (CH) | 2016-07-26 | — | — | US | disclosed |
| US-9399021-B2 | Pharmaceutical composition | NOVARTIS AG (CH) | 2016-07-26 | — | — | US | disclosed |
| US-9271941-B2 | Pharmaceutical composition | NOVARTIS AG (CH) | 2016-03-01 | — | — | US | disclosed |
| US-20130225524-A1 | Chemical Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2013-08-29 | — | — | US | disclosed |
| EP-2556776-A1 | Method for the preparation of infusions | Paratico, Roberto (IT) | 2013-02-13 | — | — | EP | disclosed |
| US-20130018038-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2013-01-17 | — | — | US | disclosed |
| US-20130018038-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2013-01-17 | — | — | US | disclosed |
| WO-2012095388-A2 | COMPOUNDS FOR TREATMENT OF FELINE LEUKEMIA IN FELIDAE | Universität Zürich (CH) | 2012-07-19 | — | — | WO | disclosed |
| WO-2012095388-A2 | COMPOUNDS FOR TREATMENT OF FELINE LEUKEMIA IN FELIDAE | Universität Zürich (CH) | 2012-07-19 | — | — | WO | disclosed |
| US-20120077828-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2012-03-29 | — | — | US | disclosed |
| US-20120077828-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2012-03-29 | — | — | US | disclosed |
| US-20070053851-A1 | Orally effective, essentially water-free topical agent containing one or several oxidation-sensitive substances | DSM IP ASSETS B.V. (NL) | 2007-03-08 | — | — | US | disclosed |
| US-20070053851-A1 | Orally effective, essentially water-free topical agent containing one or several oxidation-sensitive substances | DSM IP ASSETS B.V. (NL) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225524-A1 | Chemical Compounds | LDHA, NQO2, LDHB | DYRK1A 3147/4885BACE1 2578/4885MMP2 735/4885 |
| US-20130018038-A1 | CHEMICAL COMPOUNDS | BRCA1, IRS1, IGF1R | DYRK1A 3136/4885BACE1 139/4885MMP2 2340/4885 |
| US-20120077828-A1 | CHEMICAL COMPOUNDS | BRCA1, IRS1, IGF1R | DYRK1A 3136/4885BACE1 139/4885MMP2 2340/4885 |
| US-20160228456-A1 | COMBINATION | CYP17A1, HSD17B11, HSD17B1 | DYRK1A 2636/4885BACE1 314/4885MMP2 801/4885 |
| US-20180000774-A1 | METHODS OF TREATING COGNITIVE AND BEHAVIORAL IMPAIRMENT IN DOWN SYNDROME AND ALZHEIMERS DISEASE PATIENTS | CHAT, CAMK2A, CAMK1G | DYRK1A 49/4885BACE1 132/4885MMP2 1701/4885 |
| US-20070053851-A1 | Orally effective, essentially water-free topical agent containing one or several oxidation-sensitive substances | LPO, MPO, CAT | DYRK1A 1980/4885BACE1 2759/4885MMP2 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.